graph digitizer software package (GetData Pty Ltd)
90
Structured Review
GetData Pty Ltd
graph digitizer software package
Graph Digitizer Software Package, supplied by GetData Pty Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graph+digitizer+software+package/graph+digitizer+software/pm40247200-71-9-8
Average 90 stars, based on 1 article reviews
Graph Digitizer Software Package, supplied by GetData Pty Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graph+digitizer+software+package/graph+digitizer+software/pm40247200-71-9-8
Average 90 stars, based on 1 article reviews
graph digitizer software package - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Software:Article Title: Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China Article Snippet: .. OS 143 and PFS data were graphically extracted using the GetData Article Title: Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA. Article Snippet: Introduction: Based on data from the DESTINY-Breast03 trial, we performed a cost-effectiveness analysis of trastuzumab deruxtecan (TDXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had been previously treated with trastuzumab and a taxane from the US payer perspective.. Methods: We conducted a Markov model to assess the cost-effectiveness of T-DXd versus trastuzumab emtansine (T-DM1).. The simulation time horizon for this model was the lifetime of patients. Article Title: Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer Article Snippet: .. We utilized the GetData Article Title: Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression. Article Snippet: We conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (DESTINY-Breast04) data to evaluate the cost-effectiveness of trastuzumab deruxtecan (T-DXd) versus physician’s choice of chemotherapy (PCC) in patients with HER2-low metastatic breast cancer (MBC) from the perspectives of the United States payers and the Chinese health care system.. Our results suggest that, T-DXd was unlikely to offer a reasonable value for the money spent compared to PCC for patients with HER2-low MBC in the United States.. A value-based price for T-DXd was reduced by 51% in the United States and less than $1950 per cycle in China. Article Title: Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review. Article Snippet: Purpose: To systematically evaluate the safety, dosing regimen, and efficacy of selexipag for pediatric patients with pulmonary hypertension (PH).. Methods: A literature search of the electronic databases of PubMed, Embase, Web of Science, Cochrane Library, and Google Scholar was performed from inception through February 28, 2023.. Two reviewers independently searched and evaluated the quality of the studies and pooled data when appropriate. Article Title: Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma. Article Snippet: .. The GetData Article Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma. Article Snippet: .. Model survival and disease progression risk assessment The GetData Biomarker Discovery:Article Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma. Article Snippet: .. Model survival and disease progression risk assessment The GetData |